Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Chart Of The Day: Aldeyra - Skyrocketing
Article By:
Jim Van Meerten
Tuesday, April 11, 2023 11:15 AM EDT
Revenue is expected to grow by 2,045.80% next year. Earnings are estimated to increase by 16.90% next year and continue to compound at an annual rate of 73.70% for the next 5 years.
In this article: ALDX
RegeneRx Versus Restasis: Who Hits The $2 Billion Dry-Eye Jackpot?
Article By:
Shock Exchange
Wednesday, October 4, 2017 6:29 PM EDT
A manhunt is on for the next dry-eye disruptor. RGRX and ALDX are two candidates. RGRX just completed Phase 3 testing. Its drug has shown success in head-to-head comparisons with Restasis and Xiidra. Will RGRX hit the dry-eye jackpot?
Aldeyra Raises Additional Capital To Fund Dry Eye Treatment
Article By:
Shock Exchange
Wednesday, September 27, 2017 11:55 AM EDT
ALDX recently raised nearly $27MM to fund its dry eye treatment. Fresh capital gives ALDX flexibility to partner with big pharma for drug development or go it alone. The dry eye market offers huge upside for a new entrant. ALDX is a buy.